Medtronic heart valve replacement succeeds in intermediate-risk patients: study

WASHINGTON (Reuters) - Medtronic Plc's non-invasive transcatheter aortic valve replacement (TAVR) system proved as safe as traditional surgery in intermediate-risk patients in a two-year study presented on Friday, paving the way for its use in a wider patient population.